THE DEAL, AT A GLANCE
2/4 reviewedSereNeuro Therapeutics
SereNeuro Therapeutics
SereNeuro develops preclinical non-opioid cell and gene therapies for chronic pain.
SereNeuro Therapeutics raised Pre-Seed, announced 2026-10-0501What it doesSereNeuro develops preclinical non-opioid cell and gene therapies for chronic pain.Source-grounded · automated review · Explore ↗
Checked 2026-10-05 · Review due 2026-10-12
Read supporting source ↗SereNeuro Therapeutics is a preclinical…
02What happenedSereNeuro Therapeutics raised Pre-Seed, announced 2026-10-05From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersIts work targets osteoarthritis joint pain and nerve pain without opioids.Interpretation · Explore ↗
Checked 2026-10-05 · Review due 2026-10-12
Read supporting source ↗Our programs target chronic osteoarthritis…
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
SereNeuro Therapeutics · Financing Record
Explore source-linked visual explanations for SereNeuro Therapeutics. Unsupported claims are withheld while source review continues.
Record 13424 · Recorded date: 2026-10-05
Explore company records →